| Read Time: < 1 minute

A court in Louisiana granted the defendant’s motion to dismiss two of three product defect claims in a lawsuit.

Plaintiffs Stephanie and Robert Fuller accused the defendant, Eisai Inc. and Arena Pharmaceuticals Inc., of design defects, manufacturing defects, and safety misrepresentations related to its drug Belviq.

The weight loss drug is allegedly linked to breast cancer, according to the plaintiffs.

The court ruled that the Fullers did not provide sufficient evidence for their manufacturing defect claims, as well as their claims about breach of warranty.

The design defect claim is expected to continue to the Eastern District of Louisiana court.

Soure: Drug Watch

Author Photo

Gayle Gerling Pettinga

Born and raised in Evansville, Gayle is a respected, experienced lawyer and a valued community leader. She graduated near the top of her class at Indiana University’s prestigious Maurer School of Law. She’s practiced law with one of the largest firms in Indianapolis as well as one of the largest pharmaceutical companies in the world. And that means she knows how big law firms and big companies think and how they operate – and she will put that knowledge to work for you.

Gayle has received numerous awards and honors including Martindale-Hubbell — Peer Review Rated: AV®, American Institute of Personal Injury Attorneys 10 Best Attorneys in Indiana for Exceptional and Outstanding Client Service, and YWCA Evansville 100 Years, 100 Women Honoree, 2011.

Rate this Post

1 Star2 Stars3 Stars4 Stars5 Stars